Mahantesh Sabarad of SBICap Securities believes various sectors will be impacted by the rate of Goods and Services Tax (GST), expected to be around 18 percent.
The entire business model of pharma companies in the US comprising of substantial filings, inspection of facilities & FDA compliance and marketing distributing strategy is threatened at present, says Mahantesh Sabarad, Deputy VP Research, SBICap Securities.
Mahantesh Sabarad of SBICAP Securities is of the view that one may look at Allcargo Logistics.
Mahantesh Sabarad of SBICAP Securities is of the view that Dish TV is looking attractive.
Mahantesh Sabarad of SBICAP Securities feels that YES Bank may move to Rs 1050-1060.
Mahantesh Sabarad of SBICAP Securities is of the view that one may look at Maruti Suzuki.
Mahantesh Sabarad of SBICAP Securities suggests buying United Breweries.
Mahantesh Sabarad of SBICAP Securities is of the view that one may buy Nestle India.
Stock specific Mahantesh Sabarad of SBICAP Securities is very bullish on Nestle India and Maruti and have target price of Rs 6800 and Rs 4900 respectively.
Watch the interview of Mahantesh Sabarad of SBICap Securities with Anuj Singhal & Ekta Batra on CNBC-TV18, in which he shared his readings and outlook on market and specific stocks.
Mahantesh Sabarad, Deputy VP-Research, SBICap Securities has a cautious view on the pharma space.
Mahantesh Sabarad, Deputy VP-Research, SBICap Securities likes JK Tyre and Industries from the tyre space.
Watch the interview of Mahantesh Sabarad, Deputy VP-Research, SBICap Securities with Ekta Batra and Anuj Singhal on CNBC-TV18, in which he shared his reading and outlook on market and specific stocks.
Mahantesh Sabarad, Deputy Vice President - Research at SBI Capital Securities likes Maruti Suzuki with a target of Rs 5100 and has a target of Rs 2800 for Hero Motocorp.
Mahantesh Sabarad, Deputy Vice President - Research at SBI Capital Securities is of the view that one may prefer Power Grid.
Mahantesh Sabarad, Deputy Vice President - Research at SBI Capital Securities likes Jubilant Life Sciences.
Amongst the cement companies, Mahantesh Sabarad of SBICap Securities prefers regional players that are exposed to central and eastern parts of the country than largecap names. He likes Heidelberg from that space
Mahantesh Sabarad, Deputy VP-Research at SBI Capital Securities is of the view that HeidelbergCement India is the favourite in the cement space.
Watch the interview of Mahantesh Sabarad, Dy VP-Research at SBICap Securities with Anuj Singhal & Ekta Batra on CNBC-TV18, in which he shared his readings and outlook on market and specific stocks.
Sabarad of SBICap Securities is bullish on the infrastructure and banking themes, and wary of auto-ancillary firms with sizeable exposure to European markets.
Mahantesh Sabarad, Deputy VP - Research at SBI Capital Securities is of the view that one may look at GlaxoSmithKline Consumer Healthcare.
Mahantesh Sabarad, Deputy VP - Research at SBI Capital Securities is of the view that one may prefer Allcargo Logistics and feels that one may look at Dish TV.
Mahantesh Sabarad, Deputy VP - Research at SBI Capital Securities is of the view that one can buy Infosys.
Mahantesh Sabarad, Deputy VP - Research at SBI Capital Securities is of the view that Tata Motors appears attractive.
Mahantesh Sabarad of SBICAP Securities is bullish on financial NBFC space, select pharma companies and IT stocks. He likes PTC India, Dr Reddy's Lab, Biocon, Infosys and Firstsource, among others.